References
- Cardoso F, Harbeck N, Followfield L, et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vii11–vii19.
- Cho W. Circulating microRNAs as minimally invasive biomarkers for cancer theragnosis and prognosis. Front Genet. 2011;2:7.
- Zhao H, Shen J, Medico L, et al. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PloS One. 2010;5:e13735.
- Nilsen TW. Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet. 2007;23:243–249.
- Fan Z, Cui H, Yu H, et al. MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression. Oncogenesis. 2016;5:e197.
- Dokanehiifard S, Soltani BM, Parsi S, et al. Experimental verification of a conserved intronic microRNA located in the human TrkC gene with a cell type-dependent apoptotic function. Cell Molec Life Sci. 2015;72:2613–2625.
- Hsieh T-H, Hsu C-Y, Tsai C-F, et al. miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis. Oncotarget. 2015;6:494.
- He H, Xu F, Huang W, et al. miR-125a-5p expression is associated with the age of breast cancer patients. Genet Molec Res. 2015;14:17927–17933.
- Nishida N, Mimori K, Fabbri M, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer, and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res. 2011;17:2725–2733.
- Xu X, Lv Y-G, Yan C-Y, et al. Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling. Biochem Biophys Res Comm. 2016;479::893–900.
- Jiang L, Huang Q, Zhang S, et al. Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer. 2010;10:318.
- Jiang L, Chang J, Zhang Q, et al. MicroRNA hsa-miR-125a-3p activates p53 and induces apoptosis in lung cancer cells. Cancer Invest. 2013;31:538–544.
- Wang H, Tan G, Dong L, et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PloS One. 2012;7:e34210.
- Luo Y, Wang X, Niu W, et al. Elevated microRNA-125b levels predict a worse prognosis in HER2-positive breast cancer patients. Oncol Lett. 2017;13:867–874.
- Le MT, Shyh-Chang N, Khaw SL, et al. Conserved regulation of p53 network dosage by microRNA–125b occurs through evolving miRNA–target gene pairs. PLoS Genet. 2011;7:e1002242.